DiagnosTear Technologies（DTR）株式概要DiagnosTear Technologies Inc.は眼科企業であり、眼疾患に対する破壊的診断ソリューションの開発と商業化に従事している。 詳細DTR ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析財務データは報告されていない Canadian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( CA$17M )すべてのリスクチェックを見るDTR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.28該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesDiagnosTear Technologies Inc. 競合他社Nanalysis ScientificSymbol: TSXV:NSCIMarket cap: CA$16.6mAurora SpineSymbol: TSXV:ASGMarket cap: CA$18.0mFrequency ExchangeSymbol: TSXV:FREQMarket cap: CA$15.9mCheelcareSymbol: TSXV:CHERMarket cap: CA$35.1m価格と性能株価の高値、安値、推移の概要DiagnosTear Technologies過去の株価現在の株価CA$0.2852週高値CA$0.8852週安値CA$0.25ベータ01ヶ月の変化-5.00%3ヶ月変化-21.92%1年変化-43.00%3年間の変化n/a5年間の変化n/aIPOからの変化-59.29%最新ニュースNew Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canadaお知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).最新情報をもっと見るRecent updatesNew Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canadaお知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).お知らせ • Feb 17DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025.株主還元DTRCA Medical EquipmentCA 市場7D5.6%-1.1%-2.2%1Y-43.0%-23.4%29.3%株主還元を見る業界別リターン: DTR過去 1 年間で-23.4 % の収益を上げたCanadian Medical Equipment業界を下回りました。リターン対市場: DTRは、過去 1 年間で29.3 % のリターンを上げたCanadian市場を下回りました。価格変動Is DTR's price volatile compared to industry and market?DTR volatilityDTR Average Weekly Movement18.8%Medical Equipment Industry Average Movement15.8%Market Average Movement10.0%10% most volatile stocks in CA Market17.4%10% least volatile stocks in CA Market3.8%安定した株価: DTRの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: DTRの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてCanadianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2023n/aShimon Grossdiagnostear.comDiagnosTear Technologies Inc.は眼科企業であり、眼疾患の破壊的診断ソリューションの開発と商業化に従事している。同社は、ドライアイ症候群（TeaR DES）の同定と監視を目的としたTeaRxプラットフォームに基づくCE-IVD承認検査であるTeaRx Dry Eye、アデノウイルス性結膜炎、ヘルペス性角膜炎、アレルギー性結膜炎の鑑別評価を目的としたTeaRx Red Eye、および1マイクロリットルの涙液を非侵襲的に採取し、下流の分析検査用にアッセイバッファーで希釈できる独自のマイクロ流体涙液コレクターであるTeaRx Tear Collectorを開発している。ダイアグノスティア・テクノロジーズ社は、以前はオーシャンビュー・テクノロジーズ社として知られていたが、ダイアグノスティア・テクノロジーズ社に社名を変更した。同社は2023年に法人化され、イスラエルのレホボトに本社を置いている。もっと見るDiagnosTear Technologies Inc. 基礎のまとめDiagnosTear Technologies の収益と売上を時価総額と比較するとどうか。DTR 基礎統計学時価総額CA$17.45m収益（TTM）CA$0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオDTR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計DTR 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$0収益CA$0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%DTR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 11:59終値2026/06/10 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DiagnosTear Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).
お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada
お知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.
お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.
お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.
New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).
New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).
お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada
お知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.
お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.
お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.
New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).
お知らせ • Feb 17DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025.
